 |
|
Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy
An Underestimated Phenomenon
Hans-Martin M. B. Otten, MD, PhD;
Joost Mathijssen, MD;
Hugo ten Cate, MD, PhD;
Marcel Soesan, MD;
Marijke Inghels, MD;
Dick J. Richel, MD, PhD;
Martin H. Prins, MD, PhD
Arch Intern Med. 2004;164:190-194.
ABSTRACT
| |
Background The exact incidence of venous thromboembolism (VTE) in cancer patients is unknown, partly because of confounding factors. Prophylactic treatment is warranted in surgical patients with cancer because of a high incidence of VTE. We performed a retrospective study to evaluate if the same applies for cancer patients treated with chemotherapy.
Methods The medical records of 206 consecutive patients with malignancy, treated with chemotherapy, were identified. The kind of malignancy and chemotherapeutic treatment were recorded, as was the date of treatment. The records were reviewed for other risk factors for VTE, and were searched for proved deep venous thrombosis or pulmonary embolism.
Results Of those 206 patients, 15 (7.3%) had proved VTE during or within 3 months after chemotherapeutic treatment. The annual incidence was 10.9%. The incidence of VTE was specifically high in the 39 patients treated with a combination of fluorouracil and leucovorin calcium because of colorectal cancer (6 [15%] of the patients were affected). The occurrence of VTE in the latter group of patients was not influenced by factors such as surgery, central venous catheters, or tumor load.
Conclusions The annual incidence of VTE in patients treated with chemotherapy was high, specifically in patients with colorectal cancer treated with fluorouracil-leucovorin. If these observations are confirmed, trials to evaluate the use of prophylactic anticoagulant treatment should be conducted.
INTRODUCTION
The relation between cancer and venous thromboembolism (VTE) has been known since at least 1865, and it is generally accepted that the incidence of VTE in cancer patients is high.1 Nevertheless, the true incidence of VTE in cancer patients is unknown. One of the reasons for this lack of clarity is the presence of confounding factors. Most cancer patients need surgery for their malignancy, will be exposed to chemotherapy and/or intravenous catheters, and may become immobilized during their disease. The relation between VTE and (different kinds of) chemotherapy has been most extensively investigated in patients with breast cancer.2-11 In patients with breast cancer stage I or II, the incidence of VTE seemed to increase from 0.2% to 2.0% in those receiving chemotherapy. In most of those studies, patients were also treated with tamoxifen citrate, which itself is thrombogenic.12 In patients with high-grade glioma treated with chemotherapy, the incidence of VTE was 12% in a prospective study13 and 16% in a retrospective study.14 Finally, Grem et al15 reported an incidence of 17% in 36 patients with unresectable or metastatic colon carcinoma treated with a combination of fluorouracil and leucovorin calcium and granulocyte-macrophage colony-stimulating factor. These data suggest a significantly increased risk for VTE in patients with different kinds of malignancies who are receiving chemotherapy.
In general, prevention for VTE is not given to patients with cancer being treated with chemotherapy. However, in analogy with surgical patients, such a prophylaxis might be warranted if the incidence of VTE was demonstrated to be high enough.16-19
Therefore, we performed a retrospective study to evaluate the incidence of VTE among consecutive patients treated with chemotherapy for malignant disease in a teaching hospital in Amsterdam.
METHODS
STUDY DESIGN AND POPULATION
We performed a retrospective, single-institution, cohort study. In the Slotervaart Hospital, all patients are registered according to the Systematic Information center for Health Care system, the Dutch medical registration system. This registration system enabled us to identify all patients, aged at least 18 years, treated with chemotherapy because of malignant disease between January 1, 1995, and January 1, 2000. A search of the registration systems of the internal medicine department and the oncology nurses revealed no additional cases. After identification, the computerized and the medical records of each patient were retrieved and evaluated. The data were retrieved according to the local rules of the medical ethical board.
DATA RETRIEVAL
Besides the age and sex of the patients, the kind of malignant disease and the various chemotherapeutic agents administered to each patient were recorded. We retrieved the exact date the chemotherapy was started and stopped. Furthermore, we reviewed the records of all patients for the exact date and kind of surgery (if any) and the introduction of central venous catheters. In addition, we registered the use of coumarin or heparin calcium derivatives. The radiological history of all patients was checked for the performance of ultrasonography of the extremities, a ventilation-perfusion lung scan, and/or pulmonary angiography. In all patients with proved VTE, we actively searched the records and radiological reports for indicators of tumor load at the time of VTE.
STUDY DEFINITIONS
The malignant disease had to be proved by histological and/or cytological reports according to current standards. The stages of the various cancers are according to the definitions used by the American Joint Committee on Cancer/Union Internationale Contre le Cancer.20 The stage of disease was considered a marker for the tumor load. The criterion for deep venous thrombosis by compression ultrasonography was noncompressibility of a proximal vein.21 A perfusion-ventilation scan was diagnostic for a pulmonary embolism if the perfusion scan showed one or more segmental defects and the ventilation scan showed no abnormalities in the same segment(s) (mismatch).22-24 In case of a subsegmental mismatch or a matched defect (perfusion and ventilation defect), pulmonary angiography had to demonstrate pulmonary emboli.25
ANALYSIS
The incidence of VTE, for the entire group of patients, was expressed as a proportion and as an annual incidence. For this latter purpose, we considered the patients at risk for VTE during the treatment with chemotherapy and the first 13 weeks after the last treatment in analogy to postsurgical patients.26 We counted the periods at risk for VTE for all patients, and calculated the years at risk for VTE and the subsequent incidence of VTE per year. In addition, the proportion of patients with VTE was calculated for subgroups of patients defined by type of cancer and chemotherapeutic regimen. If fewer than 6 patients had a specific hematological or solid malignancy, we rubricated them as "other hematological" and "other solid," respectively. If fewer than 6 patients were treated with a specific (combination of) chemotherapeutic agent(s), we classified them as "other for hematological malignancy" and "other for solid malignancy," depending on the underlying malignancy.
If applicable, the 95% confidence interval was calculated using statistical software (StatXact, version 3.0; Cytel Software Corp, Cambridge, Mass).
RESULTS
PATIENT POPULATION
In total, 209 patients with cancer who were treated with chemotherapy because of malignant disease were identified. For 206 (98.6%) of these patients, the hospital medical records were available for review. The mean age at the start of chemotherapy was 58 years (range, 20-88 years), and 116 patients (55.5%) were women. The most common malignancies were colorectal carcinoma, non-Hodgkin disease, breast carcinoma, ovarian carcinoma, multiple myeloma, and Kaposi sarcoma (Table 1). In 8 (3.8%) of the 209 patients, central venous catheter (7 Port-A-Cath systems [Deltec, Inc, St Paul, Minn] and 1 percutaneously inserted central venous catheter) access was present, because of medication or feeding (n = 5) or inaccessible peripheral veins (n = 3). In 94 (45.6%) of the 206 patients, surgical treatment had preceded the chemotherapeutic treatment. The mean interval between surgery and chemotherapy was 7.9 weeks (range, 2-34 weeks). The average period of chemotherapeutic treatment was 22.6 weeks (range, 1-145 weeks). One patient received anticoagulant treatment because of a heart valve prosthesis. Two patients were immobile during the chemotherapeutic treatment. None of the patients was treated with epoetin alfa.
|
|
|
|
Table 1. Incidence of VTE in Relation to Type of Malignancy
|
|
|
INCIDENCE OF VTE
Overall, 15 (7.3%) of the 206 patients had a proved VTE during, or within 3 months after, chemotherapy. The characteristics of these patients are shown in Table 2. One patient had a retinal vein thrombosis. Two patients had an upper limb thrombosis, 4 had a pulmonary embolism (fatal in 2 of them), and 8 had a deep venous thrombosis of the lower limb. Of these latter 8 patients, 2 had bilateral deep venous thrombosis.
|
|
|
|
Table 2. Characteristics of the Patients With a VTE During or Within 12 Weeks After Chemotherapeutic Treatment
|
|
|
In the entire group of patients, the annual incidence of VTE was 10.9% (95% confidence interval, 6.1%-18.0%).
RISK FACTORS FOR VTE
Surgery
None of the patients with VTE underwent surgery in the 12 weeks preceding chemotherapeutic treatment. In 5 patients, surgery had been performed 13 to 39 weeks (mean, 21.5 weeks) before the initiation of chemotherapeutic treatment.
Central Venous Catheters
One of the patients with a central venous catheter had a symptomatic deep venous thrombosis a year before the implantation of a central venous access device (Port-A-Cath); none of the others experienced signs of VTE.
Timing of VTE With Regard to Chemotherapy
Nine patients had a VTE during their chemotherapeutic treatment. In 2 patients, the VTE became symptomatic within a week after their last treatment. Two patients experienced the first symptoms within a month and 2 within 2 months after their last treatment.
Chemotherapeutic Treatment
The incidence of VTE in relation to chemotherapeutic regimen is given in Table 3. Venous thromboembolism was most frequent in the 41 patients treated with 5 daily bolus injections of fluorouracil-leucovorin every month (6 [15%] of these 41 patients had a VTE; 95% confidence interval, 6%-29%). Of these patients, 18 had a limited colorectal carcinoma (Dukes classification C) and were treated in an adjuvant setting. In 3 (17%) of these 18 patients, a VTE occurred.
|
|
|
|
Table 3. Incidence of VTE in Relation to Type of Chemotherapeutic Regimen
|
|
|
Tumor Load
Tumor load was limited in 4 patients with a VTE, of whom 3 had a colorectal carcinoma. The disease of the other patients was extensive, with multiple metastases, stage III multiple myeloma, or stage IV non-Hodgkin disease.
COMMENT
Our retrospective analysis indicates that among patients with malignant disease treated with chemotherapy, the risk of symptomatic VTE is high, with an annual incidence of 10.9%. In general, VTE occurred in all subgroups, defined by kind of malignancy, extent of malignancy, and chemotherapeutic regimen. The observed incidence of VTE is in concordance with the incidence reported by others,2-7,13-14 as mentioned before. This also applies to the remarkably high incidence (6 [15%] of 39 patients) in those with colorectal carcinoma treated with fluorouracil-leucovorin.15
Our study had several limitations. Because of its retrospective nature, the data could be underestimated. We could only detect patients with symptomatic and objectively proved VTE, and could have missed patients with subtle clinical manifestations of VTE or patients who were treated for probable VTE without performing adequate diagnostic tests. On the other hand, the high incidence could be solely because of chance and could represent a high variation of the normal spectrum.
Because of the relatively few patients, it was impossible to demonstrate a statistically significant difference between the subgroups.
We were not able to find a matched control group because of highly standardized treatment policies for cancer patients in our hospital. In earlier treatment studies of cancer patients comparing a chemotherapeutic regimen with placebo, the occurrence of VTE was seldom mentioned in the toxicity score.
It is unlikely that the high incidence of VTE in patients with colorectal carcinoma treated with fluorouracil-leucovorin can be attributed to the colorectal carcinoma alone: in large epidemiological studies,27-29 the reported incidence of VTE in patients with colorectal malignancies did not differ from incidences in patients with other adenocarcinomas. Most patients with breast carcinoma were treated with a fluorouracil-containing chemotherapeutic regimen as well, so it is unlikely that fluorouracil alone is responsible for the excess of VTE in the patients treated with fluorouracil-leucovorin.
Several mechanisms have been proposed to be responsible for the hypercoagulable state of cancer patients treated with chemotherapy. Alterations in coagulation factors,30-33 anticoagulant proteins,34-36 and endothelial cells33, 37-42 have been shown to occur following the administration of various cytotoxic agents. In an experimental model, the endothelium of fluorouracil-treated rabbits was badly damaged, leading to intima disruption and denudation of underlying structures, with accompanying platelet accumulation and fibrin formation.43 Two groups31-32 demonstrated a significant increase in fibrinopeptide A levels in patients treated with fluorouracil.
Others34-36 discovered a reduction of protein C levels of different degrees during treatment with cyclophosphamide, methotrexate, and fluorouracil, but a link to clinically apparent VTE could not be made. Therefore, the exact pathophysiological mechanism for the observed excess of VTE in our group of patients remains to be determined.
In conclusion, the annual incidence of VTE in patients treated with chemotherapy in this study is high (10.9%). A remarkably high incidence of VTE was shown in patients with a colorectal malignancy treated with fluorouracil-leucovorin (15%). Before recommending prophylactic anticoagulant treatment to this category of patients, the observation should be confirmed and the efficacy and safety of the anticoagulants in this setting should be tested; the effect on mortality and the impact on the quality of life of these patients should be tested as well.
AUTHOR INFORMATION
Corresponding author: Hans-Martin M. B. Otten, MD, PhD, Department of Internal Medicine, Slotervaart Hospital, Room 0059B, Louwesweg 6, 1066 EC Amsterdam, the Netherlands (e-mail: j.m.otten{at}amc.uva.nl).
Accepted for publication February 26, 2003.
From the Departments of Medical Oncology (Drs Otten and Richel) and Vascular Medicine (Dr Mathijssen), Academic Medical Center, Amsterdam, the Netherlands; the Department of Internal Medicine, Slotervaart Hospital, Amsterdam (Drs Otten, Soesan, and Inghels); and the Departments of Hematology (Dr ten Cate) and Clinical Epidemiology (Dr Prins), Academic Hospital Maastricht, Maastricht, the Netherlands. The authors have no relevant financial interest in this article.
REFERENCES
1. Trousseau A. Phlegmasia alba dolens. In: Balliere J, ed. Clinique Medicale de l'Hotel-Dieu de Paris. 2nd ed. Paris, France: JB Baillière & Fils; 1865:654-712.
2. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-294.
ABSTRACT
3. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677-679.
ISI
| PUBMED
4. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12:1266-1271.
FREE FULL TEXT
5. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407.
ABSTRACT
6. von Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol. 1996;14:2560-2568.
ABSTRACT
7. Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor–positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2078-2085.
FREE FULL TEXT
8. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005-1018.
ABSTRACT
9. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J, National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731-2737.
FREE FULL TEXT
10. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
FULL TEXT
|
ISI
| PUBMED
11. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer. 1984;54:1264-1268.
FULL TEXT
|
ISI
| PUBMED
12. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608-612.
FULL TEXT
|
ISI
| PUBMED
13. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer. 1997;33:1592-1596.
14. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer. 1991;68:2621-2624.
FULL TEXT
|
ISI
| PUBMED
15. Grem JL, McAtee N, Murphy RF, et al. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol. 1994;12:560-568.
ABSTRACT
16. Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. BMJ. 1982;284:375-379.
17. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg. 1988;208:227-240.
ISI
| PUBMED
18. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162-1173.
ISI
| PUBMED
19. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152-156.
FULL TEXT
|
ISI
| PUBMED
20. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours/UICC. 4th ed (corrected 2nd ed). Berlin, Germany: Springer-Verlag; 1999.
21. Lensing AW, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989;320:342-345.
ABSTRACT
22. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest. 1985;88:819-828.
FREE FULL TEXT
23. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2759.
ABSTRACT
24. Hull RD, Raskob GE, Pineo GF, Brant RF. The low-probability lung scan: a need for change in nomenclature. Arch Intern Med. 1995;155:1845-1851.
ABSTRACT
25. Dalen JE, Brooks HL, Johnson LW, Meister SG, Szucs MM Jr, Dexter L. Pulmonary angiography in acute pulmonary embolism: indications, techniques, and results in 367 patients. Am Heart J. 1971;81:175-185.
FULL TEXT
|
ISI
| PUBMED
26. Kearon C, Salzman EW, Hirsh J. Epidemiology, pathogenesis and natural history of venous thrombosis. In: Colman RW, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1153-1160.
27. Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308:891-894.
FREE FULL TEXT
28. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-1173.
FREE FULL TEXT
29. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
FULL TEXT
|
ISI
| PUBMED
30. Canobbio L, Fassio T, Ardizzoni A, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer. 1986;58:1032-1036.
FULL TEXT
|
ISI
| PUBMED
31. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990;65:885-889.
FULL TEXT
|
ISI
| PUBMED
32. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 1990;89:25-28.
FULL TEXT
|
ISI
| PUBMED
33. Zurborn KH, Gram J, Glander K, et al. Influence of cytostatic treatment on the coagulation system and fibrinolysis in patients with non–Hodgkin's lymphomas and acute leukemias. Eur J Haematol. 1991;47:55-59.
ISI
| PUBMED
34. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6:276-281.
ABSTRACT
35. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989;63:1303-1307.
FULL TEXT
|
ISI
| PUBMED
36. Rella C, Coviello M, Giotta F, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996;40:151-159.
FULL TEXT
|
ISI
| PUBMED
37. Lazo JS. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol. 1986;35:1919-1923.
FULL TEXT
|
ISI
| PUBMED
38. Nicolson GL, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell–endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res. 1985;45:331-336.
FREE FULL TEXT
39. Orr FW, Adamson IY, Young L. Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury. Cancer Res. 1986;46:891-897.
FREE FULL TEXT
40. Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984;101:41-44.
41. Harrell RM, Sibley R, Vogelzang NJ. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin. Am J Med. 1982;73:429-433.
FULL TEXT
|
ISI
| PUBMED
42. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis. 1990;8:511-518.
FULL TEXT
|
ISI
| PUBMED
43. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning. 2001;23:1-8.
ISI
| PUBMED
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment
Brown and Herrington
Journal of Pharmacy Practice 2008;21:126-137.
ABSTRACT
The Risk of Venous Thromboembolism in Patients with Cancer
Khorana et al.
Am Soc Clin Oncol Ed Book 2008;2008:240-248.
ABSTRACT
| FULL TEXT
Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance
O'Connell et al.
JCO 2006;24:4928-4932.
ABSTRACT
| FULL TEXT
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients
Caruso et al.
Blood 2006;108:2216-2222.
ABSTRACT
| FULL TEXT
Proximal Deep Vein Thrombosis After Hip Replacement for Oncologic Indications
Nathan et al.
JBJS 2006;88:1066-1070.
ABSTRACT
| FULL TEXT
Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival
Alcalay et al.
JCO 2006;24:1112-1118.
ABSTRACT
| FULL TEXT
Deep vein thrombosis in cancer: the scale of the problem and approaches to management
Falanga and Zacharski
Ann Oncol 2005;16:696-701.
ABSTRACT
| FULL TEXT
Tamoxifen: Preventing Breast Cancer and Placing the Risk of Deep Vein Thrombosis in Perspective
Goldhaber
Circulation 2005;111:539-541.
FULL TEXT
|
